Want to see ZVRA full AI Analyst Report?
Total Valuation
Zevra Therapeutics has a market cap or net worth of $663.91M. The enterprise value is $659.49.
Market Cap$663.91M
Enterprise Value$659.49
Share Statistics
Zevra Therapeutics has 59,383,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,383,780
Owned by Insiders1.48%
Owned by Institutions22.38%
Financial Efficiency
Zevra Therapeutics’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -1.65%.
Return on Equity (ROE)0.54
Return on Assets (ROA)0.29
Return on Invested Capital (ROIC)-1.65%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee1.75M
Profits Per Employee1.36M
Employee Count61
Asset Turnover0.37
Inventory Turnover9.47
Valuation Ratios
The current PE Ratio of Zevra Therapeutics is 11.8. Zevra Therapeutics’s PEG ratio is -0.04.
PE Ratio11.8
PS Ratio4.65
PB Ratio3.20
Price to Fair Value3.20
Price to FCF-203.69
Price to Operating Cash Flow20.05
PEG Ratio-0.04
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 106.47M and earned 83.23M in profits. Earnings per share was 1.40.
Revenue106.47M
Gross Profit89.99M
Operating Income-4.23M
Pretax Income86.68M
Net Income83.23M
EBITDA98.71M
Earnings Per Share (EPS)1.40
Cash Flow
In the last 12 months, operating cash flow was 33.40M and capital expenditures -775.00K, giving a free cash flow of 32.62M billion.
Operating Cash Flow33.40M
Free Cash Flow32.62M
Free Cash Flow per Share0.55
Dividends & Yields
Zevra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change23.04%
50-Day Moving Average12.25
200-Day Moving Average10.12
Relative Strength Index (RSI)48.75
Average Volume (3m)1.53M
Important Dates
Zevra Therapeutics upcoming earnings date is Nov 11, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Zevra Therapeutics as a current ratio of 5.68, with Debt / Equity ratio of 0.69%
Current Ratio5.68
Quick Ratio5.63
Debt to Market Cap0.12
Net Debt to EBITDA<0.01
Interest Coverage Ratio-0.53
Taxes
In the past 12 months, Zevra Therapeutics has paid 3.45M in taxes.
Income Tax3.45M
Effective Tax Rate0.04
Enterprise Valuation
Zevra Therapeutics EV to EBITDA ratio is 5.03, with an EV/FCF ratio of -204.02.
EV to Sales4.66
EV to EBITDA5.03
EV to Free Cash Flow-204.02
EV to Operating Cash Flow-310.63
Balance Sheet
Zevra Therapeutics has $221.57M in cash and marketable securities with $1.50M in debt, giving a net cash position of $220.07M billion.
Cash & Marketable Securities$221.57M
Total Debt$1.50M
Net Cash$220.07M
Net Cash Per Share$3.71
Tangible Book Value Per Share$2.60
Margins
Gross margin is 94.96%, with operating margin of -3.98%, and net profit margin of 78.17%.
Gross Margin94.96%
Operating Margin-3.98%
Pretax Margin81.41%
Net Profit Margin78.17%
EBITDA Margin92.71%
EBIT Margin88.90%
Analyst Forecast
The average price target for Zevra Therapeutics is $25.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.25
Price Target Upside165.23% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast119.40%
EPS Growth Forecast―